Analysis of Dr. Lal PathLabs Limited (LALPATHLAB)
Dr. Lal PathLabs Limited is showing a bullish trend based on the recent data. The Relative Strength Index (RSI) is above 70, indicating an overbought condition, but the Moving Average Convergence Divergence (MACD) is positive, with the MACD line above the signal line and the MACD histogram showing an increasing trend.
The closing prices have been consistently increasing over the past few days, reaching a high of 2630.45. The Moving Average (MA) indicator is also showing an upward trend, with the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) all trending upwards.
Overall, based on the technical indicators, Dr. Lal PathLabs Limited seems to be in a strong bullish phase, with potential for further price appreciation. However, investors should also consider other factors such as market conditions and company fundamentals before making any investment decisions.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided yet. The previous results from February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at a specific time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.
Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.
1. Financials:
- Cash Flow: Operating cash flow TTM is $110,563,000,320 and levered free cash flow TTM is $84,726,874,112.
- Balance Sheet: Total cash MRQ is $67,150,000,128, total debt MRQ is $104,590,000,128, current ratio MRQ is 1.037, book value per share MRQ is $4.837, total cash per share MRQ is $4.379, and total debt to equity MRQ is 140.968.
- Profit Margin: 26.306%
- Income Statement: EBITDA is $131,393,000,000, revenue TTM is $381,623,009,280, diluted EPS TTM is $6.44, gross profit TTM is $169,148,000,000, revenue per share TTM is $24.537, net income to common TTM is $100,389,003,264, quarterly revenue growth is -4.3%, and quarterly earnings growth YoY is -2.2%.
- Operating Margin: 30.743%
- Return on Assets TTM: 22.073999%
- Return on Equity TTM: 147.25%
- Fiscal Year Ends: September 30, 2023
- Most Recent Quarter: March 31, 2024
2. Stock Statistics:
- Short Ratio: 1.66
- Float Shares: 15,308,320,742
- Shares Short: 94,308,265
- Average 10-Day Volume: 52,903,608
- Average 90-Day Volume: 62,823,269
- Shares Outstanding: 15,334,099,968
- Percent Held by Insiders: 5.22%
- Percent Held by Institutions: 57.555%
- Short Percent of Shares Outstanding: 0.62%
3. Valuation Metrics:
- PEG Ratio: 26.213001
- Forward PE: 26.213001
- Trailing PE: 29.428572
- Enterprise Value: $2,948,462,018,560
- Price to Book MRQ: 39.181313
- Price to Sales TTM: 7.6151557
- Enterprise to EBITDA: 22.745
- Enterprise to Revenue: 7.726
- Market Capitalization: $2,906,118,684,672
4. Stock Price Summary:
- Beta: 1.264
- 50-Day Moving Average: $173.6936
- 200-Day Moving Average: $180.7906
- 52-Week Low: $164.08
- 52-Week High: $199.62
- 52-Week Change: 8.253%
5. Dividends and Splits:
- Payout Ratio: 14.93%
- Dividend Date: May 16, 2024
- Last Split Date: August 31, 2020
- Ex-Dividend Date: May 10, 2024
- Last Split Factor: 4-for-1 split
- Forward Annual Dividend Rate: $1
- 5-Year Average Dividend Yield: 0.73%
- Forward Annual Dividend Yield: 0.5266761603816345%
- Trailing Annual Dividend Rate: $0.97
- Trailing Annual Dividend Yield: 0.5108758755701854%
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:
1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:
1. The current year growth rate is estimated to be 7.5%.
2. The next quarter growth rate is expected to be 4.8%.
3. The current quarter growth rate is projected to be 5.6%.
4. The next year growth rate is forecasted to be 9.7%.
5. The average annual growth rate for the next 5 years is estimated to be 11%.
6. The average annual growth rate for the past 5 years has been 20.15%.
These estimates suggest that the company is expected to experience moderate growth in the short term, with a slightly higher growth rate projected for the next year. However, the company has shown a significantly higher growth rate over the past 5 years compared to the forecasted growth for the next 5 years.
Price target
The analysts' forecast for the future price of the security is as follows:
- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price is below both the average and median forecast, indicating that there is potential upside according to the analysts' predictions.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:
1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From these figures, we can observe the following trends:
- The company experienced a decrease in revenue from FY 2022 to FY 2023.
- Prior to the decrease, there was a consistent increase in revenue over the previous two fiscal years.
- The revenue in FY 2023 is still higher compared to FY 2021 and FY 2020.
These trends indicate fluctuations in the company's revenue performance over the past four years, with a notable decrease in the most recent fiscal year.
Balance Sheet
These are balance sheets. Here are the conclusions:
1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:
1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant variability, with large amounts being spent on common stock repurchase and debt issuance/payments.
6. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial activities show a mix of stability in operations and variability in financing and investing decisions.
Earnings estimate
Based on analysts' estimates for future quarterly and annual earnings per share:
1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, with a low estimate of $1.27 and a high estimate of $1.36. This shows growth compared to the EPS of $1.26 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, with a low estimate of $1.44 and a high estimate of $1.63. This indicates an increase from the EPS of $1.46 in the same quarter last year.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.59, with a low estimate of $6.43 and a high estimate of $6.92. This reflects growth compared to the EPS of $6.13 from the previous fiscal year.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average EPS estimate is $7.23, with a low estimate of $6.40 and a high estimate of $7.90. This forecast suggests an increase from the EPS of $6.59 in the current fiscal year.
Overall, the analysts' estimates point towards a positive outlook for the company's earnings per share, with expected growth in both the quarterly and annual results over the specified periods.MACD of LALPATHLAB